Targeting serious conditions stemming from protein misfolding, where our therapeutic approach can make a meaningful difference.
We target a range of serious conditions stemming from protein misfolding, where our therapeutic approach can make a meaningful difference.
Our lead program targeting light chain amyloidosis with PROT-001.
Addressing muscle and heart conditions caused by protein dysfunction.
Targeting protein misfolding in cerebrovascular and kidney disorders.
Developing treatments for vision-threatening protein misfolding diseases.
Restoring proper function of ion channel proteins.
Combating progressive conditions linked to protein aggregation.